Limited generalisability of UPLIFT findings to clinical practice

Thorax

Volumn 68, Issue 11, 2013, Pages 1066-1067

  Walker, Steven ^a,b   Fingleton, James ^a,b,c   Weatherall, Mark ^b,d   Beasley, Richard ^a,b,c,d  

^a MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

^b CAPITAL AND COAST DISTRICT HEALTH BOARD   (New Zealand)

^c VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^d UNIVERSITY OF OTAGO WELLINGTON   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

IPRATROPIUM BROMIDE; TIOTROPIUM BROMIDE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE EXACERBATION; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; INHALER; KIDNEY DISEASE; MORTALITY; NEW ZEALAND; PRIORITY JOURNAL; SIDE EFFECT;

COPD PHARMACOLOGY;

ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; FORCED EXPIRATORY VOLUME; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SCOPOLAMINE DERIVATIVES;

EID: 84885854631     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2013-203724     Document Type: Article

References (4)

1. Jenkins C, Beasley R. Tiotropium Respimat® increases the risk of mortality. Thorax 2013;68:5-7
2. Beasley R, Singh S, Loke YK, et al. Call for worldwide withdrawal of tiotropium Respimat mist inhaler. BMJ 2012;345:e7390.
3. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
4. Medsafe. Tiotropium Handihaler datasheet. Ministry of Health, New Zealand. 2011. http://www.medsafe.govt.nz/profs/datasheet/s/Spirivacap.pdf